18F-choline positron emission tomography (PET)/computed tomography (CT) is an integral part in restaging of patients with prostate cancer (PC). The aim of this study was to describe the whole-body physiologic distribution of 18F-choline and to discuss some abnormal sites of uptake not related to PC we observed. Eighty consecutive patients submitted to 18F-choline PET/CT imaging for primary staging or biochemical recurrence (prostate specific antigen rising) after treatment of PC was considered. Whole-body PET/CT was acquired approximately 40 min after 18F-choline injection. We observed physiological 18F-choline uptake in liver, pancreas, spleen, salivary and lachrymal glands and also, owing to renal excretion, in urinary tract. Other sites of less intense tracer uptake were bone marrow and intestines. We found abnormal and unexpected PET findings in 15 patients (18.7%), not owing to PC localizations. The majority of these findings were owing to inflammation (12 of 15); a case of low grade lymphoma was detected; two patients showed focal brain uptake of 18F-choline and were subsequently submitted to magnetic resonance: in one a meningioma and in the other a low-grade brain tumour were diagnosed. Accurate knowledge of the biodistribution of 18F-choline is essential for the correct interpretation of PET/CT imaging. CT enables differentiation of physiological bowel activity and 18F-choline excretion in the ureters. In our series, 18F-choline uptake in benign pathological conditions mainly included sites of inflammation; nevertheless, accumulation in tumour deposits not because PC cannot be excluded, particularly in the brain, where correlative imaging with magnetic resonance is of the utmost importance.

To assess the usefulness of a hybrid imaging system (single-photon emission computed tomography/computed tomography, SPECT/CT) for functional anatomical mapping (FAM) using various radiotracers and the additional value of fused SPECT/CT images compared with SPECT alone. Eighty-one consecutive patients studied for various clinical situations were evaluated: 10 with 111In-pentetreotide, four with 123I-meta-iodobenzylguanidine (I-MIBG), five with 99mTc-labelled red blood cells, two with 99mTc-antigranulocyte antibodies, four with 99mTc-nanocolloids, 10 with 67Ga, seven with 99mTc-methylene diphosphonate (99mTc-MDP), nine with 99mTc-sestamibi, 21 with 99mTc-tetrofosmin, two with 201Tl, three with 99mTc-ethylcysteinate dimer (ECD), one with 99mTc-hexamethylpropyleneamine oxime (99mTc-HMPAO) and three with 123I-N-w-fluoropropyl-2-beta-carbomethoxy-3-beta-(4-iodophenyl) nortropanel (FPCIT). The acquisition of both anatomical (CT) and functional (SPECT) data was performed during a single session. SPECT data were first interpreted alone and then re-evaluated with the addition of FAM. Transmission anatomical maps allowed for the precise anatomical localization of SPECT images in 79 of the 81 cases. SPECT/CT had a significant impact on the results in 33 (40.7%) of the 81 patients: FAM provided the correct localization of SPECT findings in 23 cases, allowed the definition of the functional significance of CT lesions in two and enabled the exclusion of disease in sites of physiological tracer uptake in eight. SPECT/CT with this hybrid system is a feasible technique yielding co-registered dual-modality images. FAM allows a more precise interpretation of scintigraphic studies in several cases and fused images can improve the diagnostic accuracy of SPECT in various clinical situations.

Background and aim ¹²³I-FP-CIT SPECT has been successfully used to detect the loss of dopaminergic nigrostriatal neurons in Parkinson's disease at an early stage. In this study we evaluated the capacity of ¹²³I-FP-CIT SPECT to assess bilateral dopamine transporter (DAT) loss in de-novo hemi-Parkinson's disease (PD) patients with one-sided clinical symptoms. Patients and methods Twenty-nine de-novo hemi-PD patients at an early stage (Hoehn & Yahr stage 1) and 18 gender and age matched healthy subjects were studied. SPECT imaging was always performed at 4 h post-injection. The ratios of striatal (S) to non-specific occipital (O) binding for the entire striatum (S/O), caudate nuclei (C/O), putamina (P_put/O), and the putamen to caudate nucleus index (P_put/C) were calculated in both the basal ganglia. Results In PD patients S/O, C/O and P_put/O ratio values contralateral to the clinically affected side were significantly lower (P<0.001) than in the control group (−38%, −34% and −42%, respectively). A significant reduction (P<0.001) of the striatal binding ratios was also found ipsilaterally (S/O, −31%; C/O, −28%; P_put/O, −33%). The P_put/C index was also bilaterally significantly reduced (P<0.01). DAT loss was significantly greater (P<0.001) in the contralateral than in the ipsilateral S; and putamen bilaterally presented a higher dopaminergic deficit than did caudate. Conclusion Our results indicate that semi-quantitative ¹²³I-FP-CIT SPECT detects a bilateral dopaminergic deficit in early PD with unilateral symptoms and preclinical DAT loss in the ipsilateral striatal binding, corresponding to the side not yet affected by motor signs. Semi-quantitative analysis may thus be used to diagnose PD at an early stage as well as to identify individuals developing bilateral dopaminergic damage.